Empower™ Hereditary Cancer Test
Use
Empower™ evaluates inherited mutations associated with elevated lifetime cancer risk, such as BRCA1/2 (Hereditary Breast and Ovarian Cancer syndrome) and Lynch syndrome, providing actionable information to guide early detection, inform surgical/therapeutic decisions, risk‐reducing interventions, and family risk management. It supports customizable panel selection to address diverse hereditary cancer types, facilitating identification of individuals who may benefit from targeted therapies and proactive care.
Special Instructions
Provider can select from predefined panel options (e.g., Breast STAT, Lynch, GYN Guidelines‑Based, Multi‑Cancer, Comprehensive) or build a customizable panel from over 190 genes across 12+ cancer types. Breast STAT panel offers rapid initial reporting for 10 genes within 5‑7 calendar days, with remaining genes in 2 weeks. RNA analysis is reflexively performed for detected splice‑site variants across 54 high and moderate penetrance genes when blood is the specimen and criteria are met. Family testing at same size is provided at no additional charge under certain conditions.
Limitations
RNA analysis is contingent on specific specimen type (blood) and variant type (splice‑site), with turnaround dependent on variant detection and sample collection timing. Reporting timelines vary by panel selection (i.e., STAT vs full panel). Customizable panels require appropriate selection of genes by provider. Not all variants may be detectable or reportable depending on technical or interpretive constraints of NGS and reflex workflows.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
5-14 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided